Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015246 · ClinicalTrials.gov registry record · Phase 1
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
A Phase 1 study, sponsored by Wayne State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03015246: Completed Phase 1 study, sponsored by Wayne State University.
NCT03015246 is a Phase 1 study that has completed, run by Wayne State University. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03015246, a Phase 1 study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research deals with behaviors that are part of opioid dependence. The purpose is to study how stress and medication dose can affect opioid drug use.
Primary Outcome
demand intensity (L) and demand elasticity (a) on hypothetical drug purchasing task
Interventions
- DRUG Extended release morphine
- DRUG Buprenorphine/Naloxone low dose
- DRUG Buprenorphine/Naloxone moderate dose
- DRUG Buprenorphine/Naloxone high dose
- DRUG Active stressor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-08 |
| Phase | Phase 1 |
What the finished NCT03015246 record still lists
NCT03015246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 5 interventions - of which Extended release morphine is the first listed.
NCT03015246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03015246 about?
NCT03015246 is a clinical study titled "Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence". This research deals with behaviors that are part of opioid dependence. The purpose is to study how stress and medication dose can affect opioid drug use.
What is the current status of trial NCT03015246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-12. Estimated completion is 2020-08.
What interventions are being tested in trial NCT03015246?
The interventions under investigation include: Extended release morphine (DRUG), Buprenorphine/Naloxone low dose (DRUG), Buprenorphine/Naloxone moderate dose (DRUG), Buprenorphine/Naloxone high dose (DRUG), Active stressor (DRUG).
Who is sponsoring clinical trial NCT03015246?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03015246's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia